301
© The Editor(s) (if applicable) and The Author(s), under exclusive license
to Springer Nature Switzerland AG 2021
M. S. H. Akash et al. (eds.), Endocrine Disrupting Chemicals-induced
Metabolic Disorders and Treatment Strategies, Emerging Contaminants
and Associated Treatment Technologies,
https://doi.org/10.1007/978-3-030-45923-9_18
Chapter 18
Role of Perfluoroalkyl Substances as EDCs
in Metabolic Disorders
Samia Gul Niazi, Chanda Javed, Adeel Shah, Qurat UL Ain,
and Imtiaz Mahmood Tahir
Abstract Perfluoroalkyl substances (PFASs) belong to a class of compound that
hold at least one fluorine atom, are being used in several consumer and industrial
goods because of their special chemical properties, such as the capability to repel oil
as well as water. It is of great concern that these dangerous chemical compounds are
now present in the whole global environment. Humans are exposed to the PFASs by
drinking polluted water, ingestion of contaminated seafood, inhalation of infected
indoor air, and making contact with contaminated media of any kind. A complex
state is characterized by raised level of blood glucose, abdominal obesity, abnormal
lipid amount, hypertension, and insulin resistance. It is one of the major causes for
stroke, cardiovascular disease, chronic disease of kidney, T2D, and cancers. With
increasing obesity, the incidence of metabolic syndrome is rising. Rising evidences
suggested that raised body mass index (BMI) is not only associated with calories
rich diet and sedentary lifestyle, but also coupled with extensive environmental
exposure to obesogens like perfluoroalkyl substances (PFASs). A variety of animals
studies have suggested that exposure to PFASs can impair lipids and carbohydrates
homeostasis, change composition of fatty acid, and alter adipocyte differentiation,
S. G. Niazi (*)
Hamdard Institute of Pharmaceutical Sciences, Hamdard University Islamabad Campus,
Islamabad, Pakistan
C. Javed
Shifa College of Medical Technology, Shifa Tameer-e-Millat University, Islamabad, Pakistan
A. Shah
Islamabad Diagnostic Center, Faisalabad, Pakistan
Q. U. Ain
Riphah Institute of Pharmaceutical Sciences, Riphah International University,
Lahore, Pakistan
I. M. Tahir
Directorate of Medical Sciences, Government College University Faisalabad,
Faisalabad, Pakistan
© The Editor(s) (if applicable) and The Author(s), under exclusive license
to Springer Nature Switzerland AG 2021
M. S. H. Akash et al. (eds.), Endocrine Disrupting Chemicals-induced
Metabolic Disorders and Treatment Strategies, Emerging Contaminants
and Associated Treatment Technologies,
https://doi.org/10.1007/978-3-030-45923-9_18
Chapter 18
Role of Perfluoroalkyl Substances as EDCs
in Metabolic Disorders
Samia Gul Niazi, Chanda Javed, Adeel Shah, Qurat UL Ain,
and Imtiaz Mahmood Tahir
Abstract Perfluoroalkyl substances (PFASs) belong to a class of compound that
hold at least one fluorine atom, are being used in several consumer and industrial
goods because of their special chemical properties, such as the capability to repel oil
as well as water. It is of great concern that these dangerous chemical compounds are
now present in the whole global environment. Humans are exposed to the PFASs by
drinking polluted water, ingestion of contaminated seafood, inhalation of infected
indoor air, and making contact with contaminated media of any kind. A complex
state is characterized by raised level of blood glucose, abdominal obesity, abnormal
lipid amount, hypertension, and insulin resistance. It is one of the major causes for
stroke, cardiovascular disease, chronic disease of kidney, T2D, and cancers. With
increasing obesity, the incidence of metabolic syndrome is rising. Rising evidences
suggested that raised body mass index (BMI) is not only associated with calories
rich diet and sedentary lifestyle, but also coupled with extensive environmental
exposure to obesogens like perfluoroalkyl substances (PFASs). A variety of animals
studies have suggested that exposure to PFASs can impair lipids and carbohydrates
homeostasis, change composition of fatty acid, and alter adipocyte differentiation,
S. G. Niazi (*)
Hamdard Institute of Pharmaceutical Sciences, Hamdard University Islamabad Campus,
Islamabad, Pakistan
C. Javed
Shifa College of Medical Technology, Shifa Tameer-e-Millat University, Islamabad, Pakistan
A. Shah
Islamabad Diagnostic Center, Faisalabad, Pakistan
Q. U. Ain
Riphah Institute of Pharmaceutical Sciences, Riphah International University,
Lahore, Pakistan
I. M. Tahir
Directorate of Medical Sciences, Government College University Faisalabad,
Faisalabad, Pakistan